Immitra Bio raises $2.95M for in vivo gene editing

Immitra Bio announced the successful completion of an upsized $2.95 million (CHF 2.4 million) pre-seed financing round, funds that will be used to advance the Switzerland-based startup’s in vivo gene editing treatment for an inherited anemia.

Immitra is developing a platform for scalable, one-time curative in vivo gene editing therapies based on its novel mutation-agnostic gene editing technology and digital target identification platform. The company's approach is designed to overcome key limitations of current gene editing therapies by avoiding complex ex vivo cell manipulation, patient conditioning, stem cell transplantation and personalized therapies.

The proceeds from the pre-seed round will primarily support preclinical proof-of-concept studies for Immitra’s lead candidate, IB-003, a potential one-time curative in vivo gene editing treatment for Pyruvate Kinase Deficiency, a rare inherited anemia. The financing will also support further discovery and validation work across Immitra’s pipeline, enabled by the company's digital target discovery platform, as well as continued refinement of the platform.

The round was led by Backbone Ventures and co-led by OCCIDENT, with participation from Another VC, Kickfund, Venture Kick, Zürcher Kantonalbank, FONGIT, ETH Foundation and private investors.